Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group
27 févr. 2020 17h00 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique,...
Sonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results
14 févr. 2020 17h30 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Quarterly Net Loss Reduced by 53% Compared to Prior YearYTD Net Loss Reduced by 82% Compared to Prior YearTotal YTD Revenues of $14.4 Million...
Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division
23 janv. 2020 16h43 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique,...
Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock
29 nov. 2019 16h42 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Nov. 29, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the closing of a public offering of 446,577 shares of common stock at a public...
Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock
26 nov. 2019 10h10 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the pricing of its previously announced “best efforts” public offering of shares of...
Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock
25 nov. 2019 19h54 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced the launch of a “best efforts” public offering of shares of its common stock. Dawson...
Sonoma Pharmaceuticals Reports Second Quarter FY 2020 Financial Results
14 nov. 2019 18h00 HE
|
Sonoma Pharmaceuticals, Inc.
Quarterly and YTD Reduction in Net Loss Compared to Prior Year PETALUMA, Calif., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company...
Sonoma Pharmaceuticals Announces Management Changes
01 oct. 2019 17h09 HE
|
Sonoma Pharmaceuticals, Inc.
Agreement with CEO and Interim CFO Bubba Sandford endsAmy Trombly Appointed as Interim CEO John Dal Poggetto Appointed as New CFO PETALUMA, Calif., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Sonoma...
Sonoma Pharmaceuticals Reports First Quarter FY 2020 Financial Results
13 août 2019 17h35 HE
|
Sonoma Pharmaceuticals, Inc.
Strong Quarter-Over-Quarter Performance 26% Increase in U.S. Product Revenue46% Increase in Dermatology Revenue23% Reduction in Operating Expenses PETALUMA, Calif., Aug. 13, 2019 (GLOBE...
Sonoma Pharmaceuticals Regains Compliance with Nasdaq® Minimum Bid Price Rule
12 juil. 2019 09h00 HE
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 12, 2019 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a specialty pharmaceutical company dedicated to identifying, developing and commercializing unique,...